COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies

Letter Oncology

SARS-CoV-2 antibody responses in patients with acute leukaemia

J. O'Nions et al.

LEUKEMIA (2021)

Article Hematology

Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study

Akshay Sharma et al.

Summary: This study examined the characteristics and outcomes of HSCT recipients after developing COVID-19. It found that recipients of autologous and allogeneic HSCT who develop COVID-19 have poor overall survival rates. Factors such as age, sex, and time since transplantation were associated with higher risk of mortality in HSCT recipients.

LANCET HAEMATOLOGY (2021)

Add to Collection

Article Oncology

Immunoglobin G/total antibody testing for SARS-CoV-2: A prospective cohort study of ambulatory patients and health care workers in two Belgian oncology units comparing three commercial tests

Peter van Dam et al.

Summary: The study found that COVID-19 is heavily impacting the screening, diagnosis, and treatment of cancer patients. Seroprevalence was low among cancer patients, and there were divergent results in antibody tests. The immune responses of cancer patients varied, with some showing poor humoral immune responses.

EUROPEAN JOURNAL OF CANCER (2021)

Add to Collection

Article Virology

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroconversion in hematology-oncology patients

Paul W. Bird et al.

Summary: Patients with hematological cancers may be at higher risk of severe COVID-19 after SARS-CoV-2 infection, but studies have found a low seroconversion rate in this group. However, none of these patients died or became significantly unwell despite the low immune response to the infection.

JOURNAL OF MEDICAL VIROLOGY (2021)

Add to Collection

Article Hematology

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Yair Herishanu et al.

Summary: Patients with chronic lymphocytic leukemia have a significantly impaired antibody response to the BNT162b2 mRNA COVID-19 vaccine, which is influenced by disease activity and treatment.

BLOOD (2021)

Add to Collection

Article Hematology

Risk Factors and Mortality of COVID-19 in Patients With Lymphoma: A Multicenter Study

Isabel Regalado-Artamendi et al.

Summary: This study examined the impact of COVID-19 on patients with lymphoma, finding that factors like age, confusion, urea concentration, and respiratory rate, as well as active disease, were associated with higher mortality risk. Additionally, continued presence of the virus after week six significantly increased mortality rates.

HEMASPHERE (2021)

Add to Collection

Article Immunology